Arcutis Biotherapeutics, Inc.

NasdaqGS:ARQT Voorraadrapport

Marktkapitalisatie: US$1.2b

Arcutis Biotherapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Arcutis Biotherapeutics is Frank Watanabe, benoemd in Jan2016, heeft een ambtstermijn van 8.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.94M, bestaande uit 12.8% salaris en 87.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.56% van de aandelen van het bedrijf, ter waarde $ 6.69M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 4.5 jaar.

Belangrijke informatie

Frank Watanabe

Algemeen directeur

US$4.9m

Totale compensatie

Percentage CEO-salaris12.8%
Dienstverband CEO8.8yrs
Eigendom CEO0.6%
Management gemiddelde ambtstermijn3yrs
Gemiddelde ambtstermijn bestuur4.5yrs

Recente managementupdates

Recent updates

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Nov 15

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Sep 23
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Jul 17
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Jun 21
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

May 24
Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

May 20

Arcutis Biotherapeutics: Betting Big On Zoryve

May 01

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25
New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Mar 03
Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Feb 28
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Jan 31

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Oct 23
Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Aug 13
Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Aug 11
Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

May 02
Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

Analyse CEO-vergoeding

Hoe is Frank Watanabe's beloning veranderd ten opzichte van Arcutis Biotherapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$196m

Jun 30 2024n/an/a

-US$199m

Mar 31 2024n/an/a

-US$217m

Dec 31 2023US$5mUS$634k

-US$262m

Sep 30 2023n/an/a

-US$268m

Jun 30 2023n/an/a

-US$331m

Mar 31 2023n/an/a

-US$327m

Dec 31 2022US$5mUS$590k

-US$311m

Sep 30 2022n/an/a

-US$311m

Jun 30 2022n/an/a

-US$260m

Mar 31 2022n/an/a

-US$235m

Dec 31 2021US$4mUS$525k

-US$206m

Sep 30 2021n/an/a

-US$169m

Jun 30 2021n/an/a

-US$150m

Mar 31 2021n/an/a

-US$144m

Dec 31 2020US$3mUS$442k

-US$136m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$90m

Mar 31 2020n/an/a

-US$63m

Dec 31 2019US$1mUS$390k

-US$42m

Sep 30 2019n/an/a

-US$35m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$634kUS$327k

-US$19m

Compensatie versus markt: De totale vergoeding ($USD 4.94M ) Frank } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.20M ).

Compensatie versus inkomsten: De vergoeding van Frank is gestegen terwijl het bedrijf verliesgevend is.


CEO

Frank Watanabe (56 yo)

8.8yrs

Tenure

US$4,935,266

Compensatie

Mr. Todd Franklin Watanabe, also known as Frank, M.A., serves as Director of Amunix Pharmaceuticals, Inc. since June 2021. He has been President of Arcutis Biotherapeutics, Inc. (Formerly known as Arcutis...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Todd Watanabe
President8.8yrsUS$4.94m0.56%
$ 6.7m
Bhaskar Chaudhuri
Co-Founder & Independent Directorno dataUS$153.74k0.77%
$ 9.2m
Patrick Burnett
Senior VP & Chief Medical Officer4.3yrsUS$1.67m0.15%
$ 1.8m
L. Edwards
Senior VP & Chief Commercial Officer1.2yrsUS$2.03mgeen gegevens
David Topper
Senior VP & Chief Financial Officerless than a yeargeen gegevens0.041%
$ 492.5k
Rajvir Madan
Chief Digital & Technology Officer3.1yrsgeen gegevensgeen gegevens
Latha Vairavan
Vice President of Finance & Investor Relationsno datageen gegevensgeen gegevens
Courtney Barton
VP and Chief Compliance Officer & Privacy Officer3.8yrsgeen gegevensgeen gegevens
Masaru Matsuda
Senior VP2.8yrsUS$5.14m0.042%
$ 505.6k
Amanda Sheldon
Head of Corporate Communications3.3yrsgeen gegevensgeen gegevens
Ayisha Jeter
Head of Marketing & Market Access1.2yrsgeen gegevensgeen gegevens
Kent Taylor
Vice President of Sales1.8yrsgeen gegevensgeen gegevens

3.0yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ARQT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Todd Watanabe
President7.8yrsUS$4.94m0.56%
$ 6.7m
Bhaskar Chaudhuri
Co-Founder & Independent Director8.6yrsUS$153.74k0.77%
$ 9.2m
Patrick Heron
Independent Chairman of the Board8.6yrsUS$181.24k0.028%
$ 329.6k
Mark Lebwohl
Scientific Advisorno datageen gegevensgeen gegevens
Lawrence F. Eichenfield
Scientific Advisorno datageen gegevensgeen gegevens
Kim Papp
Scientific Advisorno datageen gegevensgeen gegevens
Terrie Curran
Independent Director4yrsUS$148.74k0%
$ 0
Halley Gilbert
Independent Director4.5yrsUS$148.74k0.0074%
$ 88.4k
Howard Welgus
Director4.3yrsUS$144.24k0.14%
$ 1.6m
Sue-Jean Lin
Independent Director3.4yrsUS$163.74k0.0077%
$ 91.5k
M Rico
Scientific Advisorno datageen gegevensgeen gegevens
Matt Zirwas
Scientific Advisorno datageen gegevensgeen gegevens

4.5yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ARQT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).